Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.

Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD, Brown M.

Value Health. 2009 Jul-Aug;12(5):657-65. doi: 10.1111/j.1524-4733.2008.00485.x. Review.

2.

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40. Review.

3.
4.

Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.

Owens GM, Olvey EL, Skrepnek GH, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S41-53. Review.

5.
6.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
7.

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

Kendrick M, Johnson KI.

Pharmacoeconomics. 2000 Jul;18(1):45-53. Review.

PMID:
11010603
8.

Cost-effectiveness of disease-modifying therapies in multiple sclerosis.

Manouchehrinia A, Constantinescu CS.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):592-600. doi: 10.1007/s11910-012-0291-6. Review.

PMID:
22782520
9.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

10.

Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

Guo S, Pelligra C, Saint-Laurent Thibault C, Hernandez L, Kansal A.

Pharmacoeconomics. 2014 Jun;32(6):559-72. doi: 10.1007/s40273-014-0150-1. Review.

PMID:
24643323
11.

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

Clegg A, Bryant J, Milne R.

Health Technol Assess. 2000;4(9):i-iv, 1-101. Review. No abstract available.

12.

Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Sharac J, McCrone P, Sabes-Figuera R.

Drugs. 2010 Sep 10;70(13):1677-91. doi: 10.2165/11538000-000000000-00000. Review.

PMID:
20731475
13.

Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.

Hawton A, Shearer J, Goodwin E, Green C.

Appl Health Econ Health Policy. 2013 Aug;11(4):331-41. doi: 10.1007/s40258-013-0034-0. Review.

PMID:
23637055
14.

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.

Clegg A, Bryant J.

Expert Opin Pharmacother. 2001 Apr;2(4):623-39. Review.

PMID:
11336612
15.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
16.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

17.

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.

Amato MP.

Expert Opin Pharmacother. 2004 Oct;5(10):2115-26. Review.

PMID:
15461547
18.

Clinical markers of therapeutic response to disease modifying drugs.

Pozzilli C, Prosperini L.

Neurol Sci. 2008 Sep;29 Suppl 2:S211-3. doi: 10.1007/s10072-008-0939-9. Review.

PMID:
18690494
19.

Early intervention in multiple sclerosis : better outcomes for patients and society?

Flachenecker P, Rieckmann P.

Drugs. 2003;63(15):1525-33. Review.

PMID:
12887260
20.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
Items per page

Supplemental Content

Write to the Help Desk